Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies.

Bak MJ, Wewer Albrechtsen NJ, Pedersen J, Knop FK, Vilsbøll T, Jørgensen NB, Hartmann B, Deacon CF, Dragsted LO, Holst JJ.

Diabetes Obes Metab. 2014 Nov;16(11):1155-64. doi: 10.1111/dom.12352. Epub 2014 Jul 22.

PMID:
25041349
2.

Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans.

Bak MJ, Albrechtsen NW, Pedersen J, Hartmann B, Christensen M, Vilsbøll T, Knop FK, Deacon CF, Dragsted LO, Holst JJ.

Eur J Endocrinol. 2014 Mar 8;170(4):529-38. doi: 10.1530/EJE-13-0941. Print 2014 Apr.

3.

Identification of amidated forms of GLP-1 in rat tissues using a highly sensitive radioimmunoassay.

van Delft J, Uttenthal LO, Hermida OG, Fontela T, Ghiglione M.

Regul Pept. 1997 Jun 18;70(2-3):191-8.

PMID:
9272633
4.

Comparison of sandwich enzyme-linked immunoadsorbent assay and radioimmunoassay for determination of exogenous glucagon-like peptide-1(7-36)amide in plasma.

Pridal L, Ingwersen SH, Larsen FS, Holst JJ, Adelhorst K, Kirk O.

J Pharm Biomed Anal. 1995 Jun;13(7):841-50.

PMID:
8562607
5.

A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite.

Wewer Albrechtsen NJ, Asmar A, Jensen F, Törang S, Simonsen L, Kuhre RE, Asmar M, Veedfald S, Plamboeck A, Knop FK, Vilsbøll T, Madsbad S, Nauck MA, Deacon CF, Bülow J, Holst JJ, Hartmann B.

Am J Physiol Endocrinol Metab. 2017 Sep 1;313(3):E284-E291. doi: 10.1152/ajpendo.00005.2017. Epub 2017 Apr 18.

PMID:
28420649
6.
7.
8.

A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers.

Drewes C, Nauck MA, Horn R, Holst J, Schmiegel W, Brabant G.

Acta Diabetol. 1997 Oct;34(3):230-4.

PMID:
9401646
9.
10.

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.

Diabetes Care. 1998 Nov;21(11):1925-31.

PMID:
9802745
11.

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ.

Diabetes. 2001 Mar;50(3):609-13.

13.

Evaluation of commercial ELISA and RIA for measuring porcine C-peptide: implications for research.

Graham ML, Gresch SC, Hardy SK, Mutch LA, Janecek JL, Hegstad-Davies RL.

Xenotransplantation. 2015 Jan-Feb;22(1):62-9. doi: 10.1111/xen.12143. Epub 2014 Oct 7.

PMID:
25291621
14.

Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2).

Orskov C, Holst JJ.

Scand J Clin Lab Invest. 1987 Apr;47(2):165-74.

PMID:
3576119
15.

Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet.

Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahrén B.

Diabetes Care. 1996 Aug;19(8):843-8.

PMID:
8842602
16.

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.

Diabetes. 1996 Nov;45(11):1524-30.

PMID:
8866556
17.

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.

Diabetes Care. 2000 Jun;23(6):807-12.

18.

Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.

Gutniak MK, Linde B, Holst JJ, Efendić S.

Diabetes Care. 1994 Sep;17(9):1039-44.

PMID:
7988303
19.

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.

Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ.

Metabolism. 1994 Jan;43(1):104-8.

PMID:
8289665

Supplemental Content

Support Center